Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 1Attention Deficit Disorder with Hyperactivity 1

Interventions

Specimen Handling 128Magnetic Resonance Spectroscopy 105Biopsy 76pembrolizumab 63Nivolumab 60Carboplatin 59Cisplatin 57Cyclophosphamide 53Paclitaxel 44Radiotherapy 36Bevacizumab 36Gemcitabine 34Dexamethasone 33Rituximab 26Doxorubicin 26olaparib 25Pemetrexed 25Fluorouracil 25atezolizumab 24Radiation 24Injections 23Docetaxel 23fludarabine 22durvalumab 22Vincristine 21Prednisone 21Oxaliplatin 21Ipilimumab 21Cytarabine 21venetoclax 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × N-monoacetylcystine × 30 days × Clear all
NCT04481048 2026-06-05

DoDNAC

Children's Hospital Medical Center, Cincinnati

Phase 2 Completed
25 enrolled 12 charts
CNS

Attention Deficit Disorder with Hyperactivity, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡